REGN logo

REGN Stock

Profile

Full Name:

Regeneron Pharmaceuticals, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

02 April 1991

Description:

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes drugs for the treatment of various diseases - eye diseases, allergies, infections, cardiovascular diseases, metabolic diseases, inflammatory diseases, oncology, and other rare diseases. The company was founded in 1988, with headquarters located in Tarrytown, New York. Currently, Regeneron has seven products that have received marketing approval and are sold in collaboration with Bayer and Sanofi (based on licensing agreements).

Key Details

Price

$667.00

Annual Revenue

$13.12 B(+7.76% YoY)

Annual EPS

$34.77(-9.03% YoY)

PE Ratio

16.51(-39.28% YoY)

Beta

0.74

Events Calendar

Earnings

Next earnings date:

Feb 04, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Feb 02, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

28 Jan '25 Citigroup
Neutral
27 Jan '25 Piper Sandler
Overweight
16 Jan '25 UBS
Neutral
14 Jan '25 Citigroup
Neutral
10 Jan '25 Wells Fargo
Overweight
08 Jan '25 Truist Securities
Buy
07 Jan '25 Bernstein
Outperform
17 Dec '24 Canaccord Genuity
Hold
15 Nov '24 Wolfe Research
Outperform
14 Nov '24 Citigroup
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
REGN
accessnewswire.com03 February 2025

On February 3, 2025, Bronstein, Gewirtz & Grossman, LLC, a well-known law firm, announced that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. and some of its executives. The lawsuit aims to seek compensation for investors who bought or acquired Regeneron securities from November 2, 2023, to October 30, 2024. This action is based on alleged breaches of federal securities laws during that time.

Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN
REGN
prnewswire.com03 February 2025

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm has an important message for shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Those who bought shares of REGN during the specified time are invited to reach out to the firm about the chance to be appointed as lead plaintiff.

Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky Notifies Shareholders of Regeneron Pharmaceuticals, Inc.(REGN) of a Class Action Lawsuit and an Upcoming Deadline
REGN
accessnewswire.com03 February 2025

If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery options under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126668&wire=1 or reach out to Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
REGN
accessnewswire.com02 February 2025

NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126658&wire=1 or reach out to Joseph E. Levi, Esq.

Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)
Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)
Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)
REGN
accessnewswire.com02 February 2025

NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126654&wire=1 or reach out to Joseph E. Levi, Esq.

ROSEN, NATIONALLY RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
ROSEN, NATIONALLY RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
ROSEN, NATIONALLY RECOGNIZED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - REGN
REGN
accessnewswire.com02 February 2025

NEW YORK, NY / ACCESS Newswire / February 2, 2025 / WHY: The Rosen Law Firm, a law firm focused on investor rights, is reminding buyers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities from November 2, 2023, to October 30, 2024, about the important lead plaintiff deadline on March 10, 2025. SO WHAT: If you bought Regeneron securities during this time, you might be eligible for compensation without having to pay any fees upfront, thanks to a contingency fee arrangement.

Why Are Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?
Why Are Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?
Why Are Analysts Bullish on Regeneron Pharmaceuticals, Inc. (REGN) Now?
REGN
Insider Monkey02 February 2025

We have put together a list of the 12 Best S&P 500 Stocks to Invest in Based on Analyst Recommendations. In this article, we will examine how Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) compares to other S&P 500 stocks. The year 2024 was significant for the overall market index, which saw an increase of […]

Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
REGN
accessnewswire.com02 February 2025

If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery options under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126589&wire=1 or reach out to Joseph E. Levi, Esq.

Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
REGN
accessnewswire.com02 February 2025

LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national firm focused on shareholder rights, is reminding investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN). This lawsuit addresses violations of the Securities Exchange Act of 1934. Investors who bought the Company's securities from November 2, 2023, to October 30, 2024, are urged to reach out to the firm before March 10, 2025.

Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
REGN
accessnewswire.com02 February 2025

NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you experienced a loss from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and are interested in possible recovery under federal securities laws, please click the link below for further details: https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=126541&wire=1 or reach out to Joseph E. Levi, Esq.

FAQ

  • What is the primary business of Regeneron Pharmaceuticals?
  • What is the ticker symbol for Regeneron Pharmaceuticals?
  • Does Regeneron Pharmaceuticals pay dividends?
  • What sector is Regeneron Pharmaceuticals in?
  • What industry is Regeneron Pharmaceuticals in?
  • What country is Regeneron Pharmaceuticals based in?
  • When did Regeneron Pharmaceuticals go public?
  • Is Regeneron Pharmaceuticals in the S&P 500?
  • Is Regeneron Pharmaceuticals in the NASDAQ 100?
  • Is Regeneron Pharmaceuticals in the Dow Jones?
  • When was Regeneron Pharmaceuticals's last earnings report?
  • When does Regeneron Pharmaceuticals report earnings?
  • Should I buy Regeneron Pharmaceuticals stock now?

What is the primary business of Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes drugs for the treatment of various diseases - eye diseases, allergies, infections, cardiovascular diseases, metabolic diseases, inflammatory diseases, oncology, and other rare diseases. The company was founded in 1988, with headquarters located in Tarrytown, New York. Currently, Regeneron has seven products that have received marketing approval and are sold in collaboration with Bayer and Sanofi (based on licensing agreements).

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is NASDAQ:REGN

Does Regeneron Pharmaceuticals pay dividends?

No, Regeneron Pharmaceuticals does not pay dividends

What sector is Regeneron Pharmaceuticals in?

Regeneron Pharmaceuticals is in the Healthcare sector

What industry is Regeneron Pharmaceuticals in?

Regeneron Pharmaceuticals is in the Biotechnology industry

What country is Regeneron Pharmaceuticals based in?

Regeneron Pharmaceuticals is headquartered in United States

When did Regeneron Pharmaceuticals go public?

Regeneron Pharmaceuticals's initial public offering (IPO) was on 02 April 1991

Is Regeneron Pharmaceuticals in the S&P 500?

Yes, Regeneron Pharmaceuticals is included in the S&P 500 index

Is Regeneron Pharmaceuticals in the NASDAQ 100?

Yes, Regeneron Pharmaceuticals is included in the NASDAQ 100 index

Is Regeneron Pharmaceuticals in the Dow Jones?

No, Regeneron Pharmaceuticals is not included in the Dow Jones index

When was Regeneron Pharmaceuticals's last earnings report?

Regeneron Pharmaceuticals's most recent earnings report was on 31 October 2024

When does Regeneron Pharmaceuticals report earnings?

The next expected earnings date for Regeneron Pharmaceuticals is 4 February 2025

Should I buy Regeneron Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions